Targeted drug delivery system for platinum-based anticancer drugs

Mini-Reviews in Medicinal Chemistry

Volumn 16, Issue 11, 2016, Pages 872-891

  Gao, Chuanzhu ^a,b   Zhang, Yan ^a   Chen, Ji ^a   Wang, Tianshuai ^a   Qian, Yunxu ^a   Yang, Bo ^a   Dong, Peng ^a,b   Zhang, Yingjie ^a,b  

^a KUNMING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Engineering Laboratory for Advanced Battery and Material of Yunnan Province   (China)

Author keywords

Anticancer; Drugs macrocyclic compounds system; Nanoparticle drug system; Platinum based drugs; Polymerdrug system; Review; Targeted drug delivery system

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CYCLODEXTRIN; CAPECITABINE; CARBON NANOTUBE; CARBOPLATIN; CETUXIMAB; CISPLATIN; COORDINATION POLYMER PARTICLE; DENDRIMER; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; GOLD NANOPARTICLE; GOLD NANOROD; HOLLOW PRUSSIAN BLUE NANOPARTICLE; IRINOTECAN; LIPID COATED NANOCAPSULE; LIPOSOME; MACROGOL; MAGNETIC NANOPARTICLE; MESOPOROUS SILICA NANOPARTICLE; NANOCAPSULE; NANOPARTICLE; PECTIN; PLATINUM 1,2 DIAMINOCYCLOHEXANE BISNEODECANOATE; PLATINUM BASED ANTINEOPLASTIC AGENT; POLYMER; QUANTUM DOT; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; DRUG CARRIER; MACROCYCLIC COMPOUND; PLATINUM COMPLEX;

ANTINEOPLASTIC ACTIVITY; BIOCOMPATIBILITY; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PENETRATION; DRUG RESISTANCE; DRUG RETENTION; HUMAN; IC50; MICELLE; MTT ASSAY; NANOPARTICLE DRUG DELIVERY SYSTEM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POLYMER DRUG DELIVERY SYSTEM; REVIEW; TARGETTED DRUG DELIVERY SYSTEM; ANIMAL; CHEMISTRY; NEOPLASMS; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; MACROCYCLIC COMPOUNDS; NANOPARTICLES; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; POLYMERS;

EID: 84973620718     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557516666151120115947     Document Type: Review

References (120)

1. Hannon, M.J. Metal-based anticancer drugs: from a past anchored in platinum chemistry to a post-genomic future of diverse chemistry and biology. Pure. Appl. Chem., 2007, 79, 2243-61.
2. Rosenberg, B.; VanCamp, L.; Trosko, J.E.; Mansour, V.H. Platinum compounds: a new class of potent antitumor agents. Nature, 1969, 222, 385-6.
3. Canta, A.; Chiorazzi, A.; Carozzi, V.; Meregalli, C.; Oggioni, N.; Sala, B.; Cavaletti, G. In vivo comparative study of the cytotoxicity of a liposomal formulation of cisplatin(lipoplatin(tm)). Cancer. Chemoth. Pharm., 2011, 68, 1001-8.
4. Nowotnik, D.P.; Cvitkovic, E. ProLindac(tm)(AP5346): a review of the development of an HPMA DACH platinum polymer therapeutic. Adv. Drug Deliv. Rev., 2009, 61, 1214-9.
5. Wang, X.Y.; Guo, Z.J. Targeting and delivery of platinum-based anticancer drugs. Chem. Soc. Rev., 2013, 42, 202-24.
6. Wang, A.Z.; Langer, R.; Farokhzad, O.C. Nanoparticle delivery of cancer drugs. Annu. Rev. Med., 2012, 63, 185-98.
7. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: the next generation. Cell, 2011, 144, 646-74.
8. Kango, S.; Kalia, S.; Celli, A.; Njuguna, J.; Habibi, Y.; Kumar, R. Surface modification of inorganic nanoparticles for development of organic-inorganic nanocomposites-A review. Prog. Polym. Sci., 2013, 38, 1232-61.
9. Caldorera-Moore, M.; Peppas, N.A. Micro-and nanotechnologies for intelligent and responsive biomaterial-based medical systems. Adv. Drug Deliv. Rev., 2009, 61, 1391-401.
10. Zhang, L.; Yu, F.; Cole, A.J.; Chertok, B.; David, A.E.; Wang, J.; Yang, V.C. Gum arabic-coated magnetic nanoparticles for potential application in simultaneous magnetic targeting and tumor imaging. AAPS. J., 2009, 11, 693-9.
11. Shapira, A.; Livney, Y.D.; Broxterman, H.J.; Assaraf, Y.G. (2011). Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist. Update., 2011, 14, 150-63.
12. Huang, H.C.; Barua, S.; Sharma, G.; Dey, S.K.; Rege, K. Inorganic nanoparticles forcncer imaging and therapy. J. Control Rel., 2011, 155, 344-7.
13. Nie, S.M.; Xing, Y.; Kim, G.J.; Simons, J.W. Nanotechnology applications in cancer. Annu. Rev. Biomed. Eng., 2007, 9, 257-88.
14. Comenge, J.; Sotelo, C.; Romero, F.; Gallego, O.; Barnadas, A.; Parada, T.G.C.; Puntes, V.F. Detoxifying antitumoral drugs via nanoconjugation: the case of gold nanoparticles and cisplatin. PloS one., 2012, 7, e47562.
15. Cho, K.; Wang, X.; Nie, S.; Shin, D.M. Therapeutic nanoparticles for drug delivery in cancer. Cancer Res., 2008, 14, 1310-6.
16. Fabbro, C.; Ali-Boucetta, H.; Da Ros, T.; Kostarelos, K.; Bianco, A.; Prato, M. Targeting carbon nanotubes against cancer. Chem. Commun., 2012, 48, 3911-26.
17. Butler, J.S.; Sadler, P.J. Targeted delivery of platinum-based anticancer complexes. Curr. Opin. Chem. Biol., 2013, 17, 175-88.
18. Hilder, T.A.; Hill, J.M. Modelling the encapsulation of the anticancer drug cisplatin into carbon nanotubes. Nanotechnology, 2007, 18, 275704.
19. Bottini, M.; Rosato, N.; Bottini, N. PEG-modified carbon nanotubes in biomedicine: current status and challenges ahead. Biomacromolecules, 2011, 12, 3381-93.
20. Tripisciano, C.; Kraemer, K.; Taylor, A.; Borowiak-Palen, E. Single-wall carbon nanotubes based anticancer drug delivery system. Chem. Phys. Lett., 2009, 478, 200-5.
21. Li, J.; Yap, S.Q.; Yoong, S.L.; Nayak, T.R.; Chandra, G.W.; Ang, W.H.; Panczyk, T.; Ramaprabhu, S.; Vashist, S.K.; Sheu, F.S. Carbon nanotube bottles for incorporation, release and enhanced cytotoxic effect of cisplatin. Carbon, 2012, 50, 1625-34.
22. Guven, A.; Rusakova, I.A.; Lewis, M.T.; Wilson, L.J. Cisplatin@US-tube carbon nanocapsules for enhanced chemotherapeutic delivery. Biomaterials, 2012, 33, 1455-61.
23. Li, J.; Yap, S.Q.; Chin, C.F.; Tian, Q.; Yoong, S.L.; Pastorin, G.; Ang, W.H. Platinum(iv) prodrugs entrapped within multiwalled carbon nanotubes: selective release by chemical reduction and hydrophobicity reversal. Chem. Sci., 2012, 3, 2083-7.
24. Ajima, K,; Murakami, T.; Mizoguchi, Y.; Tsuchida, K.; Ichihashi, T.; Iijima, S.; Yudasaka, M. Enhancement of in vivo anticancer effects of cisplatin by incorporation inside single-wall carbon nanohorns. ACS Nano., 2008, 2, 2057-64.
25. Karousis, N.; Tagmatarchis, N.; Tasis, D. Current progress on the chemical modification of carbon nanotubes. Chem. Rev., 2010, 110, 5366-97.
26. Bublil, E.M.; Yarden, Y. The EGF receptor family: spearheading a merger of signaling and therapeutics. Opin. Cell Biol., 2007, 19, 124-34.
27. Bhirde, A.A.; Patel, V.; Gavard, J.; Zhang, G.; Sousa, A A.; Masedunskas, A.; Rusling, J.F. Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery. ACS Nano., 2009, 3, 307-16.
28. Duncan, B.; Kim, C.; Rotello, V.M. Gold nanoparticle platforms as drug and biomacromolecule delivery systems. J. Control Rel., 2010, 148, 122-7.
29. Davis, M.E. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov., 2008, 7, 771-82.
30. Gibson, J.D.; Khanal, B.P.; Zubarev, E.R. Paclitaxel-functionalized gold nanoparticles. J. Am. Chem. Soc., 2007, 129, 11653-61.
31. Bhattacharya, R.; Mukherjee, P. Biological properties of "naked" metal nanoparticles. Adv. Drug Deliv. Rev., 2008, 60, 1289-306.
32. Giljohann, D.A.; Seferos, D.S.; Daniel, W.L.; Massich, M.D.; Patel, P.C.; Mirkin, C.A. Gold nanoparticles for biology and medicine. Angew. Chem, Int. Ed., 2010, 49, 3280-94.
33. Lu, W.; Singh, A.K.; Khan, S.A.; Senapati, D.; Yu, H.; Ray, P.C. Gold nano-popcorn-based targeted diagnosis, nanotherapy treatment, and in situ monitoring of photothermal therapy response of prostate cancer cells using surface-enhanced Raman spectroscopy. J. Am. Chem. Soc., 2010, 132, 18103-14.
34. Ren, L.; Huang, X.L.; Zhang, B.; Sun, L.P.; Zhang, Q.Q.; Tan, M.C.; Chow, G.M. Cisplatin-loaded Au-Au2S nanoparticles for potential cancer therapy: Cytotoxicity, in vitro carcinogenicity, and cellular uptake. J. Biomed. Mater. Res., Part A, 2008, 85, 787-96.
35. 4 nanoparticles for target-specific platin delivery. J. Am. Chem. Soc., 2009, 131, 4216-7.
36. Verma, A.; Stellacci, F. Effect of surface properties on nanoparticle-cell interactions. Small, 2010, 6, 12-21.
37. DavidáRobertson, J. A simple synthesis of a targeted drug delivery system with enhanced cytotoxicity. P. Chem. Commun., 2011, 47, 8530-2.
38. Brown, S.D.; Nativo, P.; Smith, J.A.; Stirling, D.; Edwards, P.R.; Venugopal, B. Wheate, N.J. Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin. J. Am. Chem. Soc., 2010, 132, 4678-84.
39. Dhar, S.; Daniel, W. L.; Giljohann, D.A.; Mirkin, C.A.; Lippard, S.J. Polyvalent oligonucleotide gold nanoparticle conjugates as delivery vehicles for platinum(IV) warheads. J. Am. Chem. Soc., 2009, 131, 14652-3.
40. von Maltzahn, G.; Park, J.H.; Agrawal, A.; Bandaru, N.K.; Das, S.K.; Sailor, M.J.; Bhatia, S.N. Computationally guided photothermal tumor therapy using long-circulating gold nanorod antennas. Cancer Res., 2009, 69, 3892-900.
41. Min, Y.; Mao, C.Q.; Chen, S.; Ma, G.; Wang, J.; Liu, Y. Combating the drug resistance of cisplatin using a platinum prodrug based delivery system. Angew. Chem. Int. Edit., 2012, 51, 6742-7.
42. Cheng, W.W.; Allen, T.M. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv. J. Control Rel., 2008, 126, 50-8.
43. Kratz, F.; Müller, I.A.; Ryppa, C.; Warnecke, A. Prodrug strategies in anticancer chemotherapy. Chem. Med. Chem., 2008, 3, 20-53.
44. Patra, C.R.; Bhattacharya, R.; Mukherjee, P. Fabrication and functional characterization of goldnanoconjugates for potential application in ovarian cancer. J. Mater. Chem., 2010, 20, 547-54.
45. Saha, P.; Descôteaux, C.; Brasseur, K.; Fortin, S.; Leblanc, V.; Parent, S.; Bérubé, G. Synthesis, antiproliferative activity and estrogen receptor a affinity of novel estradiol-linked platinum(II) complex analogs to carboplatin and oxaliplatin. Potential vector complexes to target estrogen-dependent tissues. Eur. J. Med. Chem., 2012, 48, 385-90.
46. Hong, R.; Han, G.; Fernández, J.M.; Kim, B.J.; Forbes, N.S.; Rotello, V.M. Glutathione-mediated delivery and release using monolayer protected nanoparticle carriers. J. Am. Chem. Soc., 2006, 28, 1078-9.
47. Min, Y.; Mao, C.; Xu, D.; Wang, J.; Liu, Y. Gold nanorods for platinum based prodrug delivery. Chem. Commun., 2010, 46, 8424-6.
48. Laurent, S.; Forge, D.; Port, M.; Roch, A.; Robic, C.; Vander Elst, L.; Muller, R.N. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem. Rev., 2008, 108, 2064-110.
49. Likhitkar, S.; Bajpai, A.K. Magnetically controlled release of cisplatin from superparamagnetic starch nanoparticles. Carbohydr. Polym., 2012, 87, 300-8.
50. Wang, J.Z.; Wang, X.Y.; Song, Y.J.; Wang, J.; Zhang, C.L.; Chang, C.J.; Yan, J.; Qiu, L.; Wu, M.M.; Guo, Z.J. A platinum anticancer theranostic agent with magnetic targeting potential derived from maghemite nanoparticles. Chem. Sci., 2013, 4, 2605-12.
51. Shubayev, V.I.; Pisanic II, T.R.; Jin, S. Magnetic nanoparticles for theragnostics. Adv. Drug. Deliver. Rev., 2009, 61, 467-77.
52. Xing, R.; Wang, X.; Zhang, C.; Wang, J.; Zhang, Y.; Song, Y.; Guo, Z. Superparamagnetic magnetite nanocrystal clusters as potential magnetic carriers for the delivery of platinum anticancer drugs. J. Mater. Chem., 2011, 21, 11142-9.
53. Dutta, R.K.; Sahu, S. Development of oxaliplatin encapsulated in magnetic nanocarriers of pectin as a potential targeted drug delivery for cancer therapy. Results Pharma Sci., 2012, 2, 38-45.
54. Jain, A.; Jain, S.K.; Ganesh, N.; Barve, J.; Beg, A.M. Design and development of ligand-appended polysaccharidic nanoparticles for the delivery of oxaliplatin in colorectal cancer. Nanomed-ano. Technol., 2010, 6, 179-90.
55. Wong, T.W.; Colombo,G.; Sonvico, F. Pectin matrix as oral drug delivery vehicle for colon cancer treatment. Aaps. Pharm. Sci. Tech., 2011, 12, 201-14.
56. 4 Nanoparticles for Target-Specific Platin Delivery. J. Am. Chem. Soc., 2009, 131, 4216-7.
57. Lian H.Y.; Hu, M.; Liu, C.H.; Yamauchi, Y.; Wu, K.C.W. Highly biocompatible, hollow coordination polymer nanoparticles as cisplatin carriers for efficient intracellular drug delivery. Chem Commun., 2012, 48, 5151-3.
58. Watanabe, K.; Nishio, Y.; Makiura, R.; Nakahira, A.; Kojima, C. Paclitaxel-loaded hydroxyapatite/collagen hybrid gels as drug delivery systems for metastatic cancer cells. Int. J. Pharm., 2013, 446, 81-8.
59. Callari, M.; Aldrich-Wright, J.; de Souza, P.L.; Stenzel, M.H. Polymers with platinum drugs and other macromolecular metal complexes for cancer treatment. Prog. Polym. Sci., 2014, 39, 1614-43.
60. Rieter, W.J; Pott, K.M; Taylor, K.M.L; Lin, W.B. Nanoscale coordination polymers for platinum-based anticancer drug delivery. J. Am. Chem. Soc., 2008, 130, 11584-5.
61. Novio, F; Simmchen, J; Vázquez-Mera, N; Amorín-Ferré, L; Ruiz-Molina, D. Coordination polymer nanoparticles in medicine. Coordin. Chem. Rev., 2013, 257, 2839-47.
62. Li, Z.I.; Barnes, J.C.; Bosoy, A.; Stoddart, J.F.; Zink, J.I. Mesoporous silica nanoparticles in biomedical applications. Chem. Soc. Rev., 2012, 41, 2590-605.
63. Tao, Z.; Toms, B.; Goodisman, J.; Asefa, T. Mesoporous silica microparticles enhance the cytotoxicity of anticancer platinum drugs. ACS nano., 2010, 4, 789-94.
64. Gu, J.; Su, S.; Li, Y.; He, Q.; Zhong, J.; Shi, J. Surface modification- complexation strategy for cisplatin loading in mesoporous nanoparticles. J. Phys. Chem. Lett., 2010, 1, 3446-50.
65. He, H.; Xiao, H.; Kuang, H.; Xie, Z.; Chen, X.; Jing, X.; Huang, Y. Synthesis of mesoporous silica nanoparticle-oxaliplatin conjugates for improved anticancer drug delivery. Colloid Surfaces B., 2014, 117, 75-81.
66. Habib, A.M.; Moghaddam, B.; Kirby, D.J.; Mohammed, A,R.; Perrie, Y. The role of lipid geometry in designing liposomes for the solubilisation of poorly water soluble drugs. Int. J. Pharm., 2013, 453, 225-32.
67. Harper, B.W.; Krause-Heuer, A.M.; Grant, M.P.; Manohar, M.; Garbutcheon-Singh, K.B.; Aldrich-Wright, J.R. Advances in platinum chemotherapeutics. Chem-A Eur. J., 2010, 16, 7064-77.
68. Torchilin, V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv. Drug Deliv. Rev., 2011, 63, 131-5.
69. Boulikas, T. "Clinical overview on Lipoplatin(tm): a successful liposomal formulation of cisplatin." Exp. Opin. Drug, 2009, 18, 1197-218.
70. Zisman, N.; Dos Santos, N.; Johnstone, S.; Tsang, A.; Bermudes, D.; Mayer, L.; Tardi, P. Optimizing liposomal cisplatin efficacy through membrane composition manipulations. Chem. Res. Pract., 2011, 2011.
71. Maruyama, K. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv. Drug. Deliv. Rev., 2011, 63, 161-9.
72. Butler, J.S.; Sadler, P.J. Targeted delivery of platinum-based anticancer complexes. J. Curr. Opin. Chem. Biol., 2013, 17, 175-88.
73. Gaspar, M.M.; Radomska, A.; Gobbo, O.L.; Bakowsky, U.; Radomski, M.W.; Ehrhardt, C. Targeted delivery of transferrin-conjugated liposomes to an orthotopic model of lung cancer in nude rats. J. Aerosol. Med. Pulm D., 2012, 25, 310-8.
74. Lila, A.S.A.; Kiwada, H.; Ishida, T. Selective Delivery of Oxaliplatin to Tumor Tissue by Nanocarrier System Enhances Overall Therapeutic Efficacy of the Encapsulated Oxaliplatin. Biol. Pharm. Bull., 2014, 37, 206-11.
75. Suzuki, R.; Takizawa, T.; Kuwata, Y.; Mutoh, M.; Ishiguro, N.; Utoguchi, N.; Shinohara, A.; Eriguchi, M.; Yanagie, H.; Maruyama, K. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome. Int. J. Pharm., 2008, 346, 143-50.
76. Krieger, M.L.; Eckstein, N.; Schneider, V.; Koch, M.; Royer, H.D.; Jaehde, U.; Bendas, G. Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro. Int. J. Pharm., 2010, 389, 10-7.
77. Jia, F.; Zhang, Y.; Narasimhan, B.; Mallapragada, S.K. Block copolymer-quantum dot micelles for multienzyme colocalization. Langmuir, 2012, 28, 17389-95.
78. Hu, Y.Y.; Liu, X.P.; Ma, X.; Rawal, A.; Prozorov, T.; Akinc, M.; Mallapragada, S.K.; Schmidt-Rohr, K. Biomimetic self-assembling copolymer-hydroxyapatite nanocomposites with the nanocrystal size controlled by citrate. Chem. Mater., 2011, 23, 2481-90.
79. Jia, F.; Liu, X.P.; Li, L.H.; Mallapragada, S.K.; Narasimhan, B.; Wang, Q. Multifunctional nanoparticles for targeted delivery of immune activating and cancer therapeutic agents. J. Control Rel, 2013, 172, 1020-34.
80. Lysenko, E.A.; Trusov, A.N.; Chelushkin, P.S.; Bronich, T.K.; Kabanov, A.V.; Zezin, A.B. Mixed micelles based on cationic and anionic amphiphilic diblock copolymers containing identical hydrophobic blocks. Polym. Sci. Ser. A., 2009, 51, 606-15.
81. Kim, H. J.; Miyata, K.; Nomoto, T.; Zheng, M.; Kim, A.; Liu, X.; Kataoka, K. SiRNA delivery from triblock copolymer micelles with spatially-ordered compartments of PEG shell, siRNA-loaded intermediate layer, and hydrophobic core. Biomaterials, 2014, 35, 4548-56.
82. Plummer, R.; Wilson, R.H.; Calvert, H.; Boddy, A.V.; Griffin, M.; Sludden, J.; Nishiya, T. A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. Brit. J. Cancer., 2011, 104, 593-8.
83. Zhu, L.; Torchilin, V.P. Stimulus-responsive nanopreparations for tumor targeting. Integr. Biol., 2013, 5, 96-107.
84. Torchilin, V. Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Eur. J. Pharm. Biopharm., 2009, 71, 431-44.
85. Andresen, T.L.; Thompson, D.H.; Kaasgaard, T. Enzyme-triggered nanomedicine: drug release strategies in cancer therapy (invited review). Mol. Membr. Biol., 2010, 27, 353-63.
86. Bharali, D.J.; Khalil, M.; Gurbuz, M.; Simone, T.M.; Mousa, S.A. Nanoparticles and cancer therapy: a concise review with emphasis on dendrimers. Int. J. Nanomed., 2009, 4, 1-7.
87. Oberoi, H.S.; Nukolova, N.V.; Kabanov, A.V.; Bronich, T.K. Nanocarriers for delivery of platinum anticancer drugs. Adv. Drug Deliv. Rev., 2013, 65, 1667-85.
88. Scott, R.W.; Wilson, O.M.; Crooks, R.M. Synthesis, characterization, and applications of dendrimer-encapsulated nanoparticles. J. Phys. Chem. B., 2005, 109, 692-704.
89. Gillies, E.R.; Frechet, J.M. Dendrimers and dendritic polymers in drug delivery. Drug Discov. Today, 2005, 10, 35-43.
90. Tomalia, D.A.; Reyna, L.A.; Svenson, S. Dendrimers as multipurpose nanodevices for oncology drug delivery and diagnostic imaging. Biochem. Soc. Trans., 2007, 35, 61-7.
91. Howell, B.A.; Fan, D. Poly(amidoamine) dendrimer-supported organoplatinum antitumour agents. P. Roy. A-Math. Phy., 2010, 466, 1515-26.
92. Burger, K.N.; Staffhorst, R.; de Vijlder, W.H.C.; Velinova, M.J.; Bomans, P.H.; Frederik, P.M.; de Kruijff, B. Nanocapsules: lipid-coated aggregates of cisplatin with high cytotoxicity. Nat. Med., 2002, 8, 81-4.
93. Khiati, S.; Luvino, D.; Oumzil, K.; Chauffert, B.; Camplo, M.; Barthelemy, P. Nucleoside-Lipid-Based Nanoparticles for Cisplatin Delivery. ACS Nano., 2011, 5, 8649-55.
94. Kieler-Ferguson, H.M.; Fréchet, J.M.; Szoka, F.C. Jr Clinical developments of chemotherapeutic nanomedicines: polymers and liposomes for delivery of camptothecins and platinum(II) drugs. Wiles. Nanomed. Nanobi., 2013, 5, 130-8.
95. Guo, S.; Wang, Y.; Miao, L.; Xu, Z.; Lin, C.M.; Zhang, Y.; Huang, L. Lipid-coated cisplatin nanoparticles induce neighboring effect and exhibit enhanced anticancer efficacy. ACS nano., 2013, 7, 9896-904.
96. Chacko, R.T.; Ventura, J.; Zhuang, J.; Thayumanavan, S. Polymer nanogels: A versatile nanoscopic drug delivery platform. Adv. Drug Deliv. Rev., 2012, 64, 836-51.
97. Chen, Y.; Ding, D.; Mao, Z.; He, Y.; Hu, Y.; Wu, W.; Jiang, X. Synthesis of hydroxypropylcellulose-poly (acrylic acid) particles with semi-interpenetrating polymer network structure. Biomacromolecules, 2008, 9, 2609-14.
98. Büyüktimkin, B.; Wang, Q.; Kiptoo, P.; Stewart, J.M.; Berkland, C.; Siahaan, T.J. Vaccine-like controlled-release delivery of an immunomodulating peptide to treat experimental autoimmune encephalomyelitis. Mol. Pharm., 2012, 9, 979-85.
99. Harper, B.W.; Krause-Heuer, A.M.; Grant, M.P.; Manohar, M.; Garbutcheon-Singh, K.B.; Aldrich-Wright, J.R. Advances in platinum chemotherapeutics. Chem. Eur. J., 2010, 16, 7064-77.
100. Jain, A.; Jain, S.K.; Ganesh, N.; Barve, J.; Beg, A.M. Design and development of ligand-appended polysaccharidic nanoparticles for the delivery of oxaliplatin in colorectal cancer. Nanomed-nano. Technol., 2010, 6, 179-90.
101. Haxton, K.J.; Burt, H.M. Polymeric drug delivery of platinum- based anticancer agents. J. Pharm. Sci., 2009, 98, 2299-316.
102. Campone, M. Rademaker-Lakhai, J.M.; Bennouna, J.; Howell, S.B.; Nowotnik, D.P.; Beijnen, J.H.; Schellens, J.H. Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients. Cancer. Chemoth. Pharm., 2007, 60, 523-33.
103. Maruyama, K. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Drug. Deliv. Rev., 2011, 63, 161-9.
104. Haag, R.; Kratz, F. Polymer therapeutics: concepts and applications. Angew. Chem. Int. Edit., 2006, 45, 1198-215.
105. Satchi-Fainaro, R.; Duncan, R.; Barnes, C.M. In: Polymer Therapeutics II; Springer. Berlin Heidelberg, 2006, pp. 1-65.
106. Qiu, L.Y.; Bae, Y.H. Polymer architecture and drug delivery. Pharm. Res., 2006, 23, 1-30.
107. Ledermann, J.; Harter, P.; Gourley, C.; Friedlander, M.; Vergote, I.; Rustin, G.; Matulonis, U. Olaparib maintenance therapy in platinum-sensitive relapsedov arian cancer. New. Engl. J. Med., 2012, 366, 1382-92.
108. Rice, J.R; Gerberich, J.L; Nowotnik, D.P; Howell, S.B. Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system. Clin. Cancer. Res., 2006, 12, 2248-54.
109. Kelland, L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer., 2007, 7, 573-84.
110. Rademaker-Lakhai, J.M.; Terret, C.; Howell, S.B.; Baud, C.M.; de Boer, R.F.; Pluim, D. Droz, J.P. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin. Cancer. Res., 2004, 10, 3386-95.
111. Horvath, G.; Premkumar, T.; Boztas, A.; Lee, E.; Jon, S.; Geckeler, K.E. Supramolecular Nanoencapsulation as a Tool: Solubilization of the Anticancer Drug trans-Dichloro (dipyridine) platinum(II) by Complexation with β-Cyclodextrin. Molecular pharmaceutics, 2008, 5, 358-63.
112. 50 on recovery time. Chem. Res. Toxicol., 2010, 23, 1417-26.
113. Shi, Y.; Dabrowiak, J.C. Host-guest interactions involving platinum anticancer agents. DNA binding and cytotoxicity of a β- cyclodextrin-adamantane-Pt(IV) complex. Inorg. Chim. Acta., 2012, 393, 337-9.
114. Shi, Y.; Goodisman, J.; Dabrowiak, J.C. Cyclodextrin Capped Gold Nanoparticles as a Delivery Vehicle for a Prodrug of Cisplatin. Inorg. Chem., 2013, 52, 9418-26.
115. Davis, F.; Higson, S. Macrocycles: construction, chemistry and nanotechnology applications, John Wiley & Sons., 2011, 77-117.
116. Brown, S.D.; Plumb, J.A.; Johnston, B.F.; Wheate, N.J. Folding of dinuclear platinum anticancer complexes within the cavity of para-sulphonatocalix arene. Inorg. Chim. Acta., 2012, 393, 182-6.
117. Krause-Heuer, A.M.; Grant, M.P.; Orkey, N.; Aldrich-Wright, J.R. Drug delivery devices and targeting agents for platinum(II) anticancer complexes. Aust. J. Chem., 2008, 61, 675-81.
118. Nojini, Z.B.; Yavari, F.; Bagherifar, S. Preference prediction for the stable inclusion complex formation between cucurbit [n=5- 7]urils with anticancer drugs based on platinum(II): Computational study. J. Mol Liq., 2012, 166, 53-61.
119. Kennedy, A.R.; Florence, A.J.; McInnes, F.J.; Wheate, N.J. A chemical preformulation study of a host-guest complex of cucurbit uril and a multinuclear platinum agent for enhanced anticancer drug delivery. Dalton. T., 2009, 37, 7695-700.
120. Jansen, B.A.; Wielaard, P.; den Dulk, H.; Brouwer, J.; Reedijk, J. Oxa-aza Crown Ethers as Ligands for Mixed-Ligand Cisplatin Derivatives and Dinuclear Platinum Anticancer Drugs. Eur. J. Inorg. Chem., 2002, 2002, 2375-9.